Chrome 2001
.
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
 
.
. .
.
Chrome 2001
Chrome 2001
Health News Health News
.
FDA To Step Up Oversight of Indian Drug Makers
February 24, 2014

 

FRIDAY, Feb. 21, 2014 (HealthDay News) -- The head of the U.S. Food and Drug Administration said Friday that her agency would increase monitoring of drugs from pharmaceutical companies in India.

As the second largest supplier of over-the-counter and prescription drugs sold in the United States, India "stands out as particularly important," FDA Commissioner Dr. Margaret Hamburg said during an afternoon news conference.

Commenting on her recent trip to India, Hamburg said she signed a non-binding "statement of intent" with Indian government officials that will lead to more cooperation between the FDA and its Indian counterpart.

As the amount of drugs made in India has increased, problems with quality have increased and the FDA has sent warning letters to several Indian drug makers in recent years, according to published reports.

"If products are sold in the United States for use by American citizens, then those products do have to meet our standards," Hamburg said.

During the press briefing, Hamburg was asked repeatedly if the FDA was singling out India.

"The fact that we have increased our presence in India is true, but it reflects the fact that India is a very significant and growing player in the U.S. marketplace," she said.

Currently, there are 12 FDA inspectors in India, and that number is expected to grow, Hamburg said.

She added that the FDA's efforts in India aren't any different from those in the United States or other countries.

"If a company is manufacturing a product for sale within the United States, they have to meet our regulatory standards and requirements," she said. "What's happening in India is consistent with what happens within the United States and throughout the world."

In 2012, India's Ranbaxy Laboratories had to recall dozens of batches of its generic version of the cholesterol-lowering drug Lipitor after the discovery of glass particles among the ingredients used in production. And last May the company's U.S. subsidiary agreed to pay $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators, the Associated Press reported.

More information

For more on FDA drug regulations, visit the U.S. Food and Drug Administration.


SOURCES: Feb. 21, 2014, press conference with Margaret Hamburg, M.D., commissioner, U.S. Food and Drug Administration; Associated Press...

InteliHealth
.
.
.
.
.
More News
InteliHealth .
.
General Health News
Today's News
Today In Health History
This Week In Health
Addiction News
Allergy News
Alzheimer's News
Arthritis News
Asthma News
Babies News
Breast Cancer News
Bronchitis News
Cancer News
Cervical Cancer News
Children's Health News
Cholesterol News
Dental/Oral Health News
Depression News
Diabetes News
Ear, Nose And Throat News
Environmental Health News
Eye News
Fitness News
Genetics News
Headache News
Health Policy News
Heart Attack News
Heart Failure News
Heart Health News
HIV/AIDS News
Infectious Diseases News
Influenza News
Lung Cancer News
Medication News
Men's Health News
Mental Health News
Multiple Sclerosis News
Nutrition News
Parkinson's News
Pregnancy News
Prostate Cancer News
Schizophrenia
Senior Health News
Sexual/Reproductive Health News
Sexual dysfunction
Sleep News
STDs News
Stroke News
Tobacco Cessation News
Weight Management News
Women's Health News
.
.
.
.
InteliHealth
    Print Printer-friendly format    
   
.  
This website is certified by Health On the Net Foundation. Click to verify.
.